NCT00449787

Brief Summary

2/3 of patients discharged from an emergency department after treatment for an acute headache will still be bothered by headache within 24 hours of emergency department (ED) treatment. The goal of this study is to compare two medications, naproxen and sumatriptan, to determine which is better for the treatment of recurrent headache within 24 hours of emergency department discharge.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
401

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Mar 2007

Typical duration for phase_4

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

March 19, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 21, 2007

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2009

Completed
3.4 years until next milestone

Results Posted

Study results publicly available

November 29, 2012

Completed
Last Updated

May 31, 2018

Status Verified

May 1, 2018

Enrollment Period

2.3 years

First QC Date

March 19, 2007

Results QC Date

July 13, 2011

Last Update Submit

May 1, 2018

Conditions

Keywords

Emergency departmentheadachemigraine

Outcome Measures

Primary Outcomes (1)

  • Numerical Rating Scale

    Within 48 hours of ED discharge, participants were allowed to take the investigational medication. At the moment they took the investigational medication, they were asked to record a number from 0 to 10, which represented their headache. 0 signified no pain and 10 signified the worse pain imaginable. Two hours later, participants were asked again to record their pain on a scale from 0 to 10. The outcome is the change in pain between baseline and two hours and will be a number between 0 and 10. Greater numbes signify greater relief

    Baseline, two hours

Secondary Outcomes (2)

  • Headache-related Functional Disability

    Baseline, two hours

  • Patient Satisfaction

    48 hours after ER discharge

Study Arms (2)

Sumatriptan

ACTIVE COMPARATOR

Sumatriptan 100 mg tablet

Drug: Sumatriptan 100 mg

Naproxen

ACTIVE COMPARATOR

Naproxen 500 mg tablet

Drug: Naproxen

Interventions

Sumatriptan 100mg tablet

Sumatriptan

Naproxen 500mg tablet

Naproxen

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Treated in the emergency department for acute primary headache

You may not qualify if:

  • Allergy, intolerance, or contra-indication to one of the study medications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Columbia University Medical Center

New York, New York, 10032, United States

Location

Montefiore Medical Center

The Bronx, New York, 10467, United States

Location

Related Links

MeSH Terms

Conditions

Migraine DisordersTension-Type HeadacheHeadache Disorders, PrimaryEmergenciesHeadache

Interventions

SumatriptanNaproxen

Condition Hierarchy (Ancestors)

Headache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

SulfonamidesAmidesOrganic ChemicalsSulfonesSulfur CompoundsTryptaminesIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsNaphthaleneacetic AcidsNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPolycyclic Compounds

Results Point of Contact

Title
Benjamin Friedman
Organization
Montefiore Medical Center

Study Officials

  • Benjamin W. Friedman, MD,MS

    Albert Einstein College of Medicine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

March 19, 2007

First Posted

March 21, 2007

Study Start

March 1, 2007

Primary Completion

July 1, 2009

Study Completion

July 1, 2009

Last Updated

May 31, 2018

Results First Posted

November 29, 2012

Record last verified: 2018-05

Locations